Skip to main content
Premium Trial:

Request an Annual Quote Lands $20M Investment From GEM Digital

NEW YORK – said Monday that it has received a $20 million financial commitment from investment firm GEM Digital.

The London-headquartered supplier of secure, blockchain-based DNA data storage and sharing services said that it will use the investment to accelerate technology development. serves both the institutional and direct-to-consumer markets.

GEM, which stands for Global Emerging Markets, is a Bahamas-based investment firm specializing in digital assets.

"Their backing will help us further realize our vision to democratize the genomics market by making it profoundly more equitable and transparent through the use of our decentralized technology," Cofounder and CEO Aldo de Pape said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.